Atypical antipsychotic drugs in the treatment of Parkinson's disease

Journal of Pharmacy Practice

Volumn 24, Issue 6, 2011, Pages 534-540

  Friedman, Joseph H ^a  

^a BROWN UNIVERSITY   (United States)

Author keywords

atypical antipsychotic drugs; delusions; first generation antipsychotics; hallucinations; neuroleptics; Parkinson's disease; Parkinson's disease psychosis; second generation antipsychotics

Indexed keywords

ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; CHOLINESTERASE INHIBITOR; CLOZAPINE; DOPAMINE 2 RECEPTOR; MELPERONE; OLANZAPINE; PLACEBO; QUETIAPINE; RISPERIDONE; ZIPRASIDONE;

AGRANULOCYTOSIS; ARTICLE; BEDTIME DOSAGE; COMPARATIVE STUDY; DOUBLE BLIND PROCEDURE; DRUG DOSE TITRATION; DRUG EFFECT; ELECTROCONVULSIVE THERAPY; EVIDENCE BASED MEDICINE; EXTRAPYRAMIDAL SYMPTOM; HUMAN; MOTOR PERFORMANCE; PARKINSON DISEASE; PARKINSON DISEASE PSYCHOSIS; PARKINSONISM; PSYCHOSIS; SEDATION; SIDE EFFECT; TARDIVE DYSKINESIA; WEIGHT GAIN;

EID: 84856061667     PISSN: 08971900     EISSN: 15311937     Source Type: Journal    
DOI: 10.1177/0897190011426556     Document Type: Article

References (67)

1. Fischer-Barnicol D, Lanquillon S, Haen E, et al. Working Group 'Drugs in Psychiatry' Typical and atypical antipsychotics-the misleading dichotomy. Results from the working group "Drugs in Psychiatry" (AGATE). Neuropsychobiology. 2008 ; 57: 80-87 (Pubitemid 351859338)
2. Farah A.. Atypicality of atypical antipsychotics. Prim Care Comp J Clin Psychiatry. 2005 ; 7: 268-274 (Pubitemid 44371604)
3. Meltzer HY.. What's atypical about atypical antipsychotic drugs?. Curr Opin Pharmacology. 2004 ; 4: 53-57 (Pubitemid 38145838)
4. Shotbolt P, Samuel M, Forx C, et al. A randomized controlled trial of quetiapine for psychosis in Parkinson's disease. Neuropsychiatric Dis Treat. 2009 ; 5: 327-332
5. Barnes J, David AS.. Visual hallucinations in Parkinson's disease: a review and phenomenological survey. J Neurol Neurosurg Psychitary. 2001 ; 70: 727-733 (Pubitemid 32554201)
6. Aarsland D, Larsen JP, Cummings JL, et al. Prevalence and clinical correlates of psychotic symptoms in Parkinson disease: a community based study. Arch Neurol. 1999; 56: 595-601
7. Papapetropoulos S, Mash DC.. Psychotic symptoms in Parkinson's disease. From description to etiology. J Neurol. 2005 ; 252: 753-764 (Pubitemid 40984849)
8. Fenelon G, Alves G.. Epidemiology of psychosis in Parkinson's disease. J Neurol Sci. 2010 ; 289: 12-17
9. Ravina B, Marder K, Fernandez HH, et al. Diagnostic criteria for psychosis in Parkinson's disease: report of an NIND, NIMH work group. Mov Disord. 2007 ; 22: 1061-1068 (Pubitemid 47067214)
10. Friedman JH.. The management of the levodopa psychoses. Clin Neuropharmacol. 1991 ; 14: 283-295
11. Kegeles LS, Abi-Dargham A, Frankle WG, et al. Increased synaptic dopamine function in associative regions of the striatum in schizophrenia. Arch Gen Psychiatry. 2010 ; 67: 231-239
12. Freyhan FA.. Comments on the biological and psychopathological basis of individual variation in chlorpromazine therapy. Encephale. 1957 ; 45: 913-919
13. Chou KL, Messing S, Oakes D, et al. Drug-induced psychosis in Parkinson disease: phenomenology and correlations among psychosis rating instruments. Clin Neuropharmacol. 2005 ; 28: 215-219 (Pubitemid 41579618)
14. Schrag A, Hovris A, Morley D, et al. Caregiver-burden in Parkinson's disease is closely associated with psychiatric symptoms, falls, and disability. Parkinsonism Relat Disord. 2006 ; 12: 35-41 (Pubitemid 43037151)
15. Goetz CG, Stebbins GT.. Risk factors for nursing home placement in advanced Parkinson's disease. Neurology. 1993 ; 43: 2227-2229 (Pubitemid 23346953)
16. Goetz CG, Fan W, Leurgans S, et al. The malignant course of "benign hallucinations" in Parkinson's disease. Arch Neurol. 2006 ; 63: 713-716
17. Goetz CG, Stebbins GT.. Mortality and hallucinations in nursing home patients with advanced Parkinson's dissase. Neurology. 1995 ; 45: 669-671
18. Moskowitz C, Moses H, Klawans HL.. Levodopa-induced psychosis: a kindling phenomenon. Am J Psychiatry. 1978 ; 135: 669-675 (Pubitemid 8344603)
19. Scholz E, Dichgans J.. Treatment of drug-induced exogenous psychosis in parkinsonism with clozapine and fluperlapine. Eur Arch Psychiatry Neurol Sci. 1985 ; 235: 60-64
20. Friedman JH, Fernandez HH.. Autopsy follow up of a patient with schizophrenia and presumed idiopathic Parkinson disease. Clin Neuropharmacol. 2001 ; 24: 120-121 (Pubitemid 32294691)
21. Wolters EC, Hurwitz TA, Mak E, et al. Clozapine in the treatment of parkinsonian patients with dopaminomimetic psychosis. Neurology. 1990 ; 40: 832-834 (Pubitemid 20159625)
22. Low dose Clozapine for the treatment of drug-induced psychosis in Parkinson's disease. New Eng J Med. 1999 ; 52: 757-763
23. Pollak P, Tison F, Rascol O, et al. Clozapine in drug induced psychosis in Parkinson's disease: a randomised, placebo controlled study with open follow up. J Neurol Neurosurg Psychiatry. 2004 ; 75: 689-695 (Pubitemid 38526677)
24. Rosebush PI, Mazurek MF.. Neurologic side effects in neuroleptic naïve patients treated with haloperidol or risperidone. Neurol. 1999 ; 52: 782-785 (Pubitemid 29120185)
25. Meco G, Alessandria A, Bonifate V, Giustini P.. Risperidone for hallucinations in levodopa treated Parkinson disease patients. Lancet. 1994 ; 343: 1370-1371 (Pubitemid 24162601)
26. Ford B, Lynch T, Greene P.. Risperidone in Parkinson's disease. Lancet. 1994 ; 344: 681
27. Rich SS, Friedman JH, Ott BR.. Risperidone versus clozapine in the treatment of psychosis in six patients with Parkinson's disease and other akinetic-rigid syndromes. J Clin Psychiatry. 1995 ; 56: 556-559 (Pubitemid 26001766)
28. Mohr E, Mendis T, Hildebrand K, et al. Risperidone in the treatment of dopamine-induced psychosis in Parkinson's disease: an open pilot trial. Mov Disord. 2000 ; 15: 1230-1237
29. McKeith IG.. Neuroleptic sensitivity to risperidone in Lewy body dementia. Lancet. 1995 ; 346: 699
30. Wolters EC, Jansen EN, Tuynman-Qua HG, et al. Olanzapine in the treatment of dopaminomimetic psychosis in patients with Parkinson's disease. Neurology. 1996 ; 47: 1085-1087
31. Ondo WG, Levy JK, Vuong KD, et al. Olanzapine treatment for dopaminergic-hallucinations. Mov Disord. 2002 ; 17: 1031-1035
32. Breier A, Sutton VK, Feldman PD, et al. Olanzapine in the treatment of dopamimetic-induced psychosis in patient with Parkinson's disease. Biol Psychiatry. 2002 ; 52: 438-445 (Pubitemid 35266735)
33. Goetz CG, Blasucci LM, Leurgans S, et al. Olanzapine and clozapine: comparative effects on motor function in hallucinating PD patients. Neurology. 2000 ; 55: 789-794
34. Friedman JH.. Olanzapine in the treatment of dopaminomimetic psychosis in patients with Parkinson's disease. Neuorlogy. 1998 ; 50: 1195-1196
35. Friedman JH, Goldstein S, Jacques C.. Substituting clozapine for olanzapine in psychiatrically stable Parkinson's disease patients: results of an open label pilot study. Clin Neuropharmacol. 1998 ; 21: 285-288 (Pubitemid 28491428)
36. Ondo WG, Tintner R, Vuong KD, et al. Double-blind, placebo-controlled, unforced titration parallel trial of quetiapine for dopaminergic-induced hallucinations in Parkinson's disease. Mov Disord. 2005 ; 20: 958-963 (Pubitemid 41419510)
37. Rabey JM, Prohorov T, Miniovich A, et al. The effect of quetiapine in Parkinson's disease (PD) psychotic patients: a double-blind labeled study of three months duration. Mov Disord. 2005 ; 20 (suppl 10). S46
38. Shotbolt P, Samuel M, Fox C, et al. A randomized controlled trial of quetiapine for psychosis in Parkinson's disease. Neuropsychiatr Dis Treat. 2009 ; 5: 327-332
39. Fernandez HH, Okun MS, Rodriguez RL, et al. Quetiapine improves visual hallucinations in Parkinson's disease but not through normalization of sleep architecture: results of a double blind clinical-polysomnograph study. Int J Neurosci. 2009 ; 119: 2196-2205
40. Morgante L, Epifanio A, Spina E, et al. Quetiapine and clozapine in parkinsonian patients with dopaminergic psychosis. Clin Neuropharmacol. 2004 ; 27: 153-156 (Pubitemid 39121725)
41. Merims D, Balas M, Peretz C, et al. Rater-blinded, prospective comparison: quetiapine versus clozapine for Parkinson's disease psychosis. Clin Neuropharmacol. 2006 ; 29: 331-337 (Pubitemid 44729944)
42. Fernandez HH, Trieschmann ME, Burke MA, et al. Long term outcome of quetiapine use for psychosis among Parkinson patients. Mov Disord. 2003 ; 18: 510-514 (Pubitemid 36656534)
43. Miyasaki JM, Shannon K, Voon V, et al. Practice Parameter: evaluation and treatment of depression, psychosis, and dementia in Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2006 ; 66: 996-1002 (Pubitemid 44044781)
44. Lopez del Val LF, Santos S.. Quetiapine and ziprasidone in the treatment of the psychotic disorders in Parkinson's disease. Rev Neurol. 2004 ; 39: 661-667 (Pubitemid 40576011)
45. Gomez-Esteban JC, Zarranz JJ, Velasco F, et al. Use of ziprasidone in parkinsonian patients with psychosis. Clin Neuropharmacol. 2005 ; 28: 111-114 (Pubitemid 40923408)
46. Schindehutte J, Trenkwalder C.. Treatment of drug-induced psychosis in Parkinson's disease with ziprasidone can induce severe dose-dependent off-periods and pathological laughing. Clin Neurol Neurosurg. 2007 ; 109: 188-191 (Pubitemid 46073393)
47. Sallee FR, Kurlan R, Goetz CG, et al. Ziprasidone in the treatment of children and adolescents with Tourette's syndrome: a pilot study. J Am Acad Psychiatry. 2000 ; 39: 292-299 (Pubitemid 30127607)
48. Friedman JH, Berman RM, Goetz CG, et al. Open-label flexible-dose pilot study to evaluate the safety and tolerability of aripiprazole in patients with psychosis associated with Parkinson's disease. Mov Disord. 2006 ; 21: 2078-2081 (Pubitemid 46140415)
49. Fernandez HH, Trieschmann ME, Friedman JH.. Aripiprazole for drug-induced psychosis in Parkinson disease: preliminary experience. Clin Neuropharmacol. 2004 ; 27: 4-5 (Pubitemid 38280379)
50. Wickremaratchi M, Morris HR, Ali IM.. Aripiprazole associated with severe exacerbation of Parkinson's disease. Mov Disord. 2006 ; 21: 1538-1539 (Pubitemid 44613323)
51. Findling RL, Robb A, Nyilis M, et al. A multiple center random double blind placebo controlled study of oral aripiprazole for treatment of adolescent schizophrenia. Am J Psychiatry. 2008 ; 165: 120-131
52. Komossa K, Rummel-Kluge C, Schmid F, et al. Aripiprazole versus other atypical antipsychotics for schizophrenia. Cochrane Schizophrenia Group. 2009 ; 4: CD006569
53. Pena MS, Yaltho TC, Jankovic J.. Tardive dyskinesia and other movement disorders secondary to aripiprazole. Mov Disord. 2011 ; 26:147-152 :
54. Barbato L, Monge A, Stocchi F, et al. Melperone in the treatment of iatrogenic psychosis in Parkinson's disease. Funct Neurol. 1996 ; 11: 201-207 (Pubitemid 26363162)
55. Kurita A, Ochiai Y, Kono Y, et al. The beneficial effect of doepezil on visual hallucinations in three patients with Parkinson's disease. J Geriatr Psychiatry Neurol. 2003 ; 16: 184-188 (Pubitemid 37409030)
56. Fabbrini G, Barbanti P, Aurilla C, et al. Donepezil in the treatment of hallucinations and delusions in Parkinson's disease. Neurol Sci. 2002 ; 23: 41-43 (Pubitemid 34591417)
57. Bergman J, Lerner V.. Successful use of donepezil for the treatment of psychotic symptoms in patient with Parkinson's disease. Clin Neukropharmacol. 2002 ; 25: 107-110 (Pubitemid 34411830)
58. Thomas AJ, Burn DJ, Rowan EN, et al. A comparison of the efficacy of donepezil in Parkinson's disease with dementia and dementia with Lewy bodies. Int J Geriatr Psychiatry. 2005 ; 20: 938-944 (Pubitemid 43055105)
59. Bullock R, Cameron A.. Rivastigmine for the treatment of dementia and visual hallucinations associated with Parkinson's disease: a case series. Curr Med Res Opin. 2002 ; 18: 258-264 (Pubitemid 35014541)
60. Reading PJ, Luce AK, McKeith IG.. Rivastigmine in the treatment of parkinsonian psychosis and cognitive impairment: preliminary findings form an open trial. Mov Disord. 2001 ; 16: 1171-1174 (Pubitemid 36041236)
61. Burn D, Emre M, McKeith I, et al. Effects of rivastigmine in patients with and without visual hallucinations in dementia associated with Parkinson's disease. Mov Disord. 2006 ; 21: 1899-1907 (Pubitemid 44848936)
62. Ueda S, Koyama K, Okubo Y.. Marked improvement of psychotic symptoms after electroconvulsive therapy in Parkinson disease. J ECT. 2010 ; 26:111-115 :
63. Factor SA, Molho ES, Brown DL.. Combined Clozapine and electroconvulsive therapy for the treatment of drug induced psychosis in Parkinson's disease. J Neuropsychiatr Clin Neurosci. 19095 ; 7: 304-307
64. Hoflich G, Burghof KW, Kasper S, et al. Electroconvulsive therapy in co morbidity of treatment refractory paranoid hallucinatory psychosis with Parkinson's disease. Nervenzart. 1994 ; 65: 202-205 (Pubitemid 24128273)
65. Eng ML, Welty TE.. Management of hallucinations and psychosis in Parkinson's disease. Am J Ger Pharmacother. 2010 ; 8: 316-330
66. Hasnain M, Vieweg WV, Baron MS, et al. Pharmacological management of psychosis in elderly patient with parkinsonism. Am J Med. 2009 ; 122: 614-622
67. Aarsland D, Marsh L, Schrag A.. Neuropsychiatric symptoms in Parkinson's disease. Mov Disord. 2009 ; 24: 2175-2186